전기생리학 기기 시장 규모, 점유율, 동향 분석 보고서 : 기기 유형별, 적응증별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Electrophysiology Devices Market Growth & Trends:

The global electrophysiology devices market size is expected to reach USD 30.09 billion by 2030, expanding at a CAGR of 15.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The demand for electrophysiology procedures is expected to increase owing to the growing geriatric population and frequent cardiac arrhythmias incidents. According to the World Health Organization, the population aged 60 years and above was approximately 1 billion in 2020 and is expected to reach 1.4 billion by 2030. The adoption of diagnostics and ablation techniques among medical professionals has resulted in the high usage of EP products in the past few years and is likely to drive market growth. The development of new products, such as Nanostim-dual-chamber leadless pacemakers, is anticipated to fuel demand for EP products.

Cardiac ablation has gained popularity as the first-line treatment, rendering a 95% success rate for several rhythm disorders, which, in turn, is boosting its demand. Technological developments, such as laser ablation, cryo-ablation, and ultrasound ablation, coupled with optimized mapping techniques are anticipated to augment market growth over the forecast period. For instance, in September 2020, Koninklijke Philips N.V. released new imaging and workflow enhancements for their novel Kodex-EPD cardiac imaging and mapping system. The market was profusely impacted by the COVID-19 pandemic. Disruptions in the supply chain and postponement of elective surgeries declined the sales of EP systems. According to a study published in the Journal of Cardiothoracic Surgery, approximately 50 to 75% of reduction in cardiac surgeries was reported during the pandemic.

The market is now revamped owing to the adoption of digital health and technological advancements in cardiac surgeries. Moreover, virtual clinics were launched for patients suffering from Atrial Fibrillation(AFib) during the pandemic. For instance, in April 2020, the Physician-Patient Alliance for Health and Safety launched Virtual Patient Care for patients suffering from AFib and had treatment with electrophysiology systems. Prominent players are adopting various strategies including new product launches andM&As to strengthen their position. For instance, in June 2020, Boston Scientific Corp. launched Directsense Technology in the U.S. It will monitor the radiofrequency energy delivery effects during the procedures for cardiac ablation. Directsense technology was approved by the U.S. FDA in April 2020 and is available on RHYTHMIA HDx Mapping System.

Electrophysiology Devices Market Report Highlights:

• Based on type, the ablation catheter segment accounted for the largest share of 45.53% of the market in 2024 due to growing heart failure and arrhythmia incidences, awareness regarding the electrophysiology procedures' reliability, and advancement in EP technologies
• Based on indication, the atrial fibrillation segment accounted for the largest market share in 2024. It is estimated to register the fastest CAGR of 15.6% during the forecast period. It is the most common type of arrhythmia associated with a high risk of stroke and blood clotting
• Inpatient facilities accounted for the largest end-use segment with over 83.47% share in 2024, attributed to the high number of surgeries performed in hospitals
• North America dominated the market with a revenue share of over 49.45% in 2024, due to the high prevalence of heart failure, growing aging population, and robust healthcare system.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Device Type
  • 1.2.2. Indication
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecast timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity price analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Device Type Segment
  • 2.2.2. Indication Segment
  • 2.2.3. End use Segment.
  • 2.2.4. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Global Electrophysiology (EP) Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Electrophysiology (EP) Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Electrophysiology (EP) Devices Market: Device Type Estimates & Trend Analysis

• 4.1. Electrophysiology (EP) Devices Market: Device Type Dashboard
• 4.2. Electrophysiology (EP) Devices Market: Device Type Movement Analysis
• 4.3. Electrophysiology (EP) Devices Market Size & Forecasts and Trend Analysis, by Device Type, 2018 to 2030 (USD Million)
• 4.4. Ablation Catheters
  • 4.4.1. Market estimates and forecast, 2018 to 2030 (USD Million)
  • 4.4.2. Radiofrequency (RF) Ablation
    • 4.4.2.1. Market estimates and forecast, 2018 to 2030 (USD Million)
  • 4.4.3. Cryoablation
    • 4.4.3.1. Market estimates and forecast, 2018 to 2030 (USD Million)
  • 4.4.4. Pulse Field Ablation
    • 4.4.4.1. Market estimates and forecast, 2018 to 2030 (USD Million)
• 4.5. Diagnostic Catheter
  • 4.5.1. Market estimates and forecast, 2018 to 2030 (USD Million)
• 4.6. Laboratory Devices
  • 4.6.1. Market estimates and forecast, 2018 to 2030 (USD Million)
• 4.7. Access Devices
  • 4.7.1. Market estimates and forecast, 2018 to 2030 (USD Million)

Chapter 5. Electrophysiology (EP) Devices Market: Indication Estimates & Trend Analysis

• 5.1. Electrophysiology (EP) Devices Market: Indication Dashboard
• 5.2. Electrophysiology (EP) Devices Market: Indication Movement Analysis
• 5.3. Electrophysiology (EP) Devices Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 5.4. Atrial Fibrillation
  • 5.4.1. Market estimates and forecast, 2018 to 2030 (USD Million)
• 5.5. Non-Atrial Fibrillation
  • 5.5.1. Market estimates and forecast, 2018 to 2030 (USD Million)

Chapter 6. Electrophysiology (EP) Devices Market: End Use Estimates & Trend Analysis

• 6.1. Electrophysiology (EP) Devices Market: End Use Dashboard
• 6.2. Electrophysiology (EP) Devices Market: End Use Movement Analysis
• 6.3. Electrophysiology (EP) Devices Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Inpatient Facilities
  • 6.4.1. Market estimates and forecast, 2018 to 2030 (USD Million)
• 6.5. Outpatient Facilities
  • 6.5.1. Market estimates and forecast, 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Market estimates and forecast, 2018 to 2030 (USD Million)

Chapter 7. Electrophysiology (EP) Devices Market: Regional Estimates & Trend Analysis by Country, Device Type, Indication, & End Use

• 7.1. Global Electrophysiology (EP) Devices Market: Regional Dashboard
• 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Regulatory framework/ reimbursement structure
    • 7.3.4.3. Competitive scenario
    • 7.3.4.4. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. UK market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. France market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.4.8. Norway
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Norway market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.4.9. Denmark
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Regulatory framework/ reimbursement structure
    • 7.4.9.3. Competitive scenario
    • 7.4.9.4. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5.3. Japan
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. India market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5.7. South Korea
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework/ reimbursement structure
    • 7.5.7.3. Competitive scenario
    • 7.5.7.4. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7.3. South Africa
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Manufacturers
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Medtronic
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Application benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Boston Scientific Corporation
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Application benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Abbott
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Application benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Biosense Webster
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Application benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. GE HealthCare
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Application benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Biotronik SE & Co. KG
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Application benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. MicroPort Scientific Corporation.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Application benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Koninklijke Philips N.V.,
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Application benchmarking
    • 8.3.11.4. Strategic initiatives